Platinum rechallenge in the era of immune checkpoint inhibitor in locally advanced/metastatic urothelial carcinoma: Multicenter retrospective study

被引：0
|
作者：
Kim, E. [1 ]
Kim, J. H. [2 ]
Chu, J. [3 ]
Lee, Y-G. [1 ]
Im, H-S. [4 ]
机构：
[1] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Hematol & Oncol, Sch Med, Seoul, South Korea
[2] Korea Univ, Anam Hosp, Dept Oncol Hematol, Seoul, South Korea
[3] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Pathol, Sch Med, Seoul, South Korea
[4] Ulsan Univ Hosp, Dept Hematol & Oncol, Ulsan, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2384P
引用
收藏
页码：S1214 / S1214
页数：1
相关论文
共 50 条
  • [41] TROPiCS-04: Study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy.
    Grivas, Petros
    Tagawa, Scott T.
    Bellmunt, Joaquim
    De Santis, Maria
    Duran, Ignacio
    Goebell, Peter-Juergen
    Necchi, Andrea
    Sridhar, Srikala S.
    Sternberg, Cora N.
    Aziz, Usman M.
    Pichardo, Cabilia C.
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [42] Clinical outcomes and treatment patterns of maintenance avelumab in locally advanced or metastatic urothelial carcinoma: a multicenter collaborative study
    Taneda, Yuki
    Urabe, Fumihiko
    Uchida, Naoki
    Kadena, Soshi
    Shibata, Ken
    Hashimoto, Masaki
    Kawano, Shota
    Takiguchi, Yuki
    Ohtsuka, Takashi
    Nakazono, Minoru
    Imai, Yu
    Iwatani, Kosuke
    Kayano, Sotaro
    Atsuta, Mahito
    Tashiro, Kojiro
    Murakami, Masaya
    Tsuzuki, Shunsuke
    Yamamoto, Toshihiro
    Yamada, Hiroki
    Miki, Jun
    Kimura, Takahiro
    JIKEI YAYOI Collaborative Grp
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2025,
  • [43] EFFICACY AND SAFETY OF IMMUNE CHECKPOINT INHIBITOR RECHALLENGE IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
    Scheiner, Bernhard
    Pomej, Katharina
    Pressiani, Tiziana
    Cammarota, Antonella
    Fruendt, Thorben W.
    Von Felden, Johann
    Schulze, Kornelius
    Roessler, Daniel
    Himmelsbach, Vera
    Finkelmeier, Fabian
    Deibel, Ansgar
    Siebenhuner, Alexander
    Shmanko, Kateryna
    Radu, Pompilia
    Schwacha, Birgit
    Ebert, Matthias P.
    Teufel, Andreas
    Djanani, Angela
    Hucke, Florian
    Balcar, Lorenz
    Venerito, Marino
    Sinner, Friedrich
    Trauner, Michael H.
    D'Alessio, Antonio
    Pinato, David James
    Peck-Radosavljevic, Markus
    Dufour, Jean-Francois
    Weinmann, Arndt
    Kremer, Andreas E.
    De Toni, Enrico
    Rimassa, Lorenza
    Pinter, Matthias
    HEPATOLOGY, 2022, 76 : S1367 - S1369
  • [44] Maintenance therapy for locally advanced or metastatic urothelial carcinoma
    Rexer, H.
    Banek, S.
    Merseburger, A.
    UROLOGIE, 2024, 63 (02): : 208 - 209
  • [45] Improved overall survival with immune checkpoint inhibitors in the treatment of metastatic urothelial carcinoma: A national retrospective comparative study
    Yu, Chih-Chin
    Su, Po-Jung
    Tsai, Yao-Chou
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
    Scheiner, Bernhard
    Roessler, Daniel
    Phen, Samuel
    Lim, Mir
    Pomej, Katharina
    Pressiani, Tiziana
    Cammarota, Antonella
    Fruendt, Thorben W.
    von Felden, Johann
    Schulze, Kornelius
    Himmelsbach, Vera
    Finkelmeier, Fabian
    Deibel, Ansgar
    Siebenhuener, Alexander R.
    Shmanko, Kateryna
    Radu, Pompilia
    Schwacha-Eipper, Birgit
    Ebert, Matthias P.
    Teufel, Andreas
    Djanani, Angela
    Hucke, Florian
    Balcar, Lorenz
    Philipp, Alexander B.
    Fulgenzi, Claudia A. M.
    Pinato, David J.
    Hsiehchen, David
    Venerito, Marino
    Sinner, Friedrich
    Trauner, Michael
    D'Alessio, Antonio
    Fulgenzi, Claudia A. M.
    Pinato, David J.
    Peck-Radosavljevic, Markus
    Dufour, Jean-Francois
    Weinmann, Arndt
    Kremer, Andreas E.
    Singal, Amit G.
    De Toni, Enrico N.
    Rimassa, Lorenza
    Pinter, Matthias
    JHEP REPORTS, 2023, 5 (01)
  • [47] Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
    Kawahara, Takashi
    Hasizume, Akihito
    Uemura, Koichi
    Yamaguchi, Katsuya
    Ito, Hiroki
    Takeshima, Teppei
    Hasumi, Hisashi
    Teranishi, Jun-ichi
    Ousaka, Kimito
    Makiyama, Kazuhide
    Uemura, Hiroji
    CANCERS, 2023, 15 (17)
  • [48] The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
    Houssiau, Helene
    Seront, Emmanuel
    CANCERS, 2022, 14 (07)
  • [49] A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma
    Gupta, Shilpa
    Moon, Helen H. -S.
    Sridhar, Srikala S.
    TARGETED ONCOLOGY, 2024, : 483 - 494
  • [50] Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma COMMENT
    Soleimani, Maryam
    Eigl, Bernhard J.
    JOURNAL OF UROLOGY, 2021, 205 (03): : 717 - 717
12345